Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Farmers Insurance
UBS
Baxter
Harvard Business School
Chinese Patent Office
Moodys
Argus Health
Chubb

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,217,057

« Back to Dashboard

Which drugs does patent 8,217,057 protect, and when does it expire?

Patent 8,217,057 protects XALKORI and is included in one NDA.

This patent has twenty-one patent family members in twenty countries.
Summary for Patent: 8,217,057
Title:Polymorphs of a c-MET/HGFR inhibitor
Abstract: This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Tran-Dube; Michelle Bich (San Diego, CA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/095,116
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 8,217,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,217,057

PCT Information
PCT FiledNovember 23, 2006PCT Application Number:PCT/IB2006/003383
PCT Publication Date:June 14, 2007PCT Publication Number: WO2007/066185

International Patents Family Members for US Patent 8,217,057

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2387650 ➤ Try a Free Trial
Russian Federation 2008120338 ➤ Try a Free Trial
Portugal 1963302 ➤ Try a Free Trial
New Zealand 568289 ➤ Try a Free Trial
South Korea 101146852 ➤ Try a Free Trial
South Korea 20080074950 ➤ Try a Free Trial
Japan 4663619 ➤ Try a Free Trial
Japan 2007153893 ➤ Try a Free Trial
Israel 191971 ➤ Try a Free Trial
Hong Kong 1126477 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Federal Trade Commission
Covington
Daiichi Sankyo
QuintilesIMS
Chubb
Fuji
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot